Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of FP-045 in Healthy Volunteers
NCT03686930Phase 1Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirivadelgat in Fanconi anemia (FA) and Peripheral Arterial Disease (PAD) (6 cohorts), sponsored by Foresee Pharmaceuticals. Primary endpoints: Change in baseline measures for vital sign parameters at 14 days, Change in baseline measures for ECG parameters at 14 days and 5 more. Started Feb 2018; status: completed.
02
Drugs
mirivadelgat
03
Conditions
Fanconi anemia (FA)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03686930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686930.